Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the bromocriptine quick release (BCQR)‐T1D study
Authors' conclusion
Objectively measured sleep <7 h per night was prevalent in adolescents and adults with T1D and associated with poorer cardiometabolic health markers. Small changes in sleep were seen following BCQR treatment in adolescents only. Sleep may be an important and novel target for improving cardiometabolic health in individuals with T1D.
Study context
- Population
- Adolescents (12–18 years) and adults (19–60 years) with T1D >9 months
- Participants
- 42 vs 42
- Comparison
- Baseline sleep <7 h per night vs ≥7 h; BCQR vs placebo
- Adolescentsn = 42
- Adultsn = 42
Methodological detailsdouble-blind, random-order, placebo-controlled, 4-week washout
- Double-blind
- Random-order
- Placebo-controlled
- 4-week washout
Primary result
As reported in the abstract
Sleep <7 h per night at baseline
Further findings
| Outcome | P value |
|---|---|
| Sleep with BCQR vs placebo (adolescents only)BCQR vs Placebo · wake time significantly later with BCQR · adolescents only | P = 0.027 |
| Sleep with BCQR vs placebo (adolescents only)BCQR vs Placebo · time in bed significantly longer with BCQR · adolescents only | P = 0.049 |
Sleep–cardiometabolic associations by age group
- Associations remained significant, predominantly for adolescents
Original publication
Sleep duration and association with cardiometabolic health in adolescents and adults with type 1 diabetes: Results from the BCQR‐T1D study. Diabetes Obes Metab. Published 8 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →